A business in context

ELTX research notebook

Read the disclosures. Follow the relationships. Keep the dates in view.

Research JSON

Filing timeline

Download filings CSV

SEC submissions · retrieved 2026-10-22 · 8029 issuers; up to 32 recent company reports and 8 ownership-change filings per issuer

  1. DEF 14A · Proxy statement

    Report date 2025-12-31 · 0001601485-26-000061

  2. 8-K · Current report

    Report date 2026-09-14 · 0001601485-26-000058 · Items 5.08,8.01

  3. 4 · Ownership change

    Report date 2026-08-31 · 0001979324-26-000002

  4. 4 · Ownership change

    Report date 2026-08-31 · 0001761748-26-000002

  5. 4 · Ownership change

    Report date 2026-08-31 · 0001441889-26-000002

  6. 4 · Ownership change

    Report date 2026-08-31 · 0001413350-26-000009

  7. 4 · Ownership change

    Report date 2026-08-31 · 0001267490-26-000010

  8. 4 · Ownership change

    Report date 2026-08-31 · 0001230486-26-000002

  9. 4 · Ownership change

    Report date 2026-08-31 · 0001187308-26-000004

  10. 10-Q · Quarterly report

    Report date 2026-06-30 · 0001601485-26-000056

  11. 8-K · Current report

    Report date 2026-08-13 · 0001601485-26-000055 · Items 2.02,9.01

  12. 4 · Ownership change

    Report date 2026-07-16 · 0001979163-26-000002

  13. 8-K · Current report

    Report date 2026-07-01 · 0001104659-26-080058 · Items 1.01,8.01,9.01

  14. 8-K · Current report

    Report date 2026-06-24 · 0001601485-26-000050 · Items 7.01

  15. 8-K · Current report

    Report date 2026-06-17 · 0001601485-26-000048 · Items 8.01

  16. 8-K · Current report

    Report date 2026-06-15 · 0001601485-26-000046 · Items 8.01

  17. 10-Q · Quarterly report

    Report date 2026-03-31 · 0001601485-26-000042

  18. 8-K · Current report

    Report date 2026-05-11 · 0001601485-26-000041 · Items 2.02,9.01

  19. 10-K/A · Annual report

    Report date 2025-12-31 · 0001601485-26-000035

  20. 8-K · Current report

    Report date 2026-03-16 · 0001601485-26-000032 · Items 1.01,1.02

  21. 10-K · Annual report

    Report date 2025-12-31 · 0001601485-26-000027

  22. 8-K · Current report

    Report date 2026-03-12 · 0001601485-26-000026 · Items 2.02

  23. 10-Q · Quarterly report

    Report date 2025-09-30 · 0001601485-25-000124

  24. 8-K · Current report

    Report date 2025-11-13 · 0001601485-25-000123 · Items 2.02

  25. 8-K · Current report

    Report date 2025-09-17 · 0001193125-25-205522 · Items 7.01,8.01,9.01

  26. 8-K · Current report

    Report date 2025-08-12 · 0001601485-25-000114 · Items 8.01

  27. 10-Q · Quarterly report

    Report date 2025-06-30 · 0001601485-25-000111

  28. 8-K · Current report

    Report date 2025-08-07 · 0001601485-25-000108 · Items 2.02

  29. 8-K · Current report

    Report date 2025-08-05 · 0001601485-25-000099 · Items 8.01

  30. 8-K · Current report

    Report date 2025-06-04 · 0001601485-25-000096 · Items 1.01,2.03,3.02,7.01,9.01

  31. 8-K · Current report

    Report date 2025-05-19 · 0001601485-25-000076 · Items 5.07

  32. 10-Q · Quarterly report

    Report date 2025-03-31 · 0001601485-25-000074

  33. 8-K · Current report

    Report date 2025-05-13 · 0001601485-25-000072 · Items 2.02

  34. DEF 14A · Proxy statement

    Report date 2025-04-09 · 0001601485-25-000062

  35. 10-K · Annual report

    Report date 2024-12-31 · 0001601485-25-000049

  36. 8-K · Current report

    Report date 2025-03-31 · 0001601485-25-000046 · Items 2.02

  37. 8-K · Current report

    Report date 2025-03-21 · 0001601485-25-000022 · Items 5.02

  38. 8-K · Current report

    Report date 2025-03-05 · 0001601485-25-000018 · Items 3.02

  39. 8-K · Current report

    Report date 2025-01-29 · 0001193125-25-016455 · Items 1.01,8.01,9.01

  40. 8-K · Current report

    Report date 2025-01-23 · 0001601485-25-000009 · Items 7.01

Reported insider transactions

Download transactions CSV

SEC insider transactions · retrieved 2026-10-15 · 2026 Q3: filings in this completed quarter; not a live transaction feed

Purchases and sales include open-market or private transactions. Grants, exercises and tax withholding are shown separately. Amendments and joint reports can overlap; rows are not a net-buying score. Prices retain the filing's units; consult its footnotes.

Transaction rows by code · counts, not monetary totals
Purchase: 0 transaction rows0PSale: 0 transaction rows0SGrant / award: 11 transaction rows11AExercise / conversion: 0 transaction rows0MTax / exercise payment: 0 transaction rows0FGift: 0 transaction rows0G
P · PurchaseS · SaleA · Grant / awardM · Exercise / conversionF · Tax / exercise paymentG · Gift

11 matching transaction rows.

Transaction / filedReporting ownerTypeSecuritySharesReported price
2026-08-31
2026-09-02
Chudnovsky YekaterinaA · Grant / award
Acquired
Stock Option (Right to Buy)
Derivative security
21750.00.0
2026-08-31
2026-09-02
Ashe Carol GailA · Grant / award
Acquired
Stock Option (Right to Buy)
Derivative security
21750.00.0
2026-08-31
2026-09-02
Nissenson AllenA · Grant / award
Acquired
Stock Option (Right to Buy)
Derivative security
21750.00.0
2026-08-31
2026-09-02
Venkatesan JayA · Grant / award
Acquired
Stock Option (Right to Buy)
Derivative security
21750.00.0
2026-08-31
2026-09-02
WILSON KAREN JA · Grant / award
Acquired
Stock Option (Right to Buy)
Derivative security
21750.00.0
2026-08-31
2026-09-02
ADAMS JULIANA · Grant / award
Acquired
Stock Option (Right to Buy)
Derivative security
21750.00.0
2026-08-31
2026-09-02
RUFFOLO ROBERT RA · Grant / award
Acquired
Stock Option (Right to Buy)
Derivative security
21750.00.0
2026-07-16
2026-07-17
DeMuth PeterA · Grant / award
Acquired
Stock Option (Right to Buy)
Derivative security
52832.00.0
2026-07-16
2026-07-17
Connelly RobertA · Grant / award
Acquired
Stock Option (Right to Buy)
Derivative security
186944.00.0
2026-07-16
2026-07-17
Shah PreetamA · Grant / award
Acquired
Stock Option (Right to Buy)
Derivative security
60833.00.0
2026-07-16
2026-07-17
Haqq ChristopherA · Grant / award
Acquired
Stock Option (Right to Buy)
Derivative security
64643.00.0

Identity & relationships

Wikidata structured data · retrieved 2026-10-15 · 1663 unambiguous CIK-linked entities; coverage is incomplete

These are sourced identity and relationship claims, with incomplete coverage. Headquarters locations do not describe sales, assets or operating exposure.

SEC issuer · 0001601485Elicio Therapeutics, Inc.

No parent relationship is available in this import; this is not proof of independence.

No verified LEI join available.

GLEIF legal entity reference data · retrieved 2026-10-15 · 1199 checked identities; 0 unavailable records

Search names and former names
  • Angion Biomedica Corp. · former SEC name · 2014-03-04 to 2023-05-30

Revenue in constant purchasing power

USD revenue expressed in 2026-09 consumer-price dollars. Each annual period uses a CPI-U average weighted by the days in its actual reporting interval. This is a purchasing-power comparison, not a company-specific price or volume measure.

Year endedReported USD revenueCPI-adjusted USD revenue
2022-12-31$2.30M$2.65M
2021-12-31$28.31M$35.20M
2020-12-31$2.88M$3.75M

Bureau of Labor Statistics · retrieved 2026-10-22 · 9 selected series; gaps remain missing

Explore the CPI history ↗